Centessa Pharmaceuticals PLC ADR (CNTA)

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US1523091007

(NASDAQ:CNTA Stock) Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Web URL: https://www.centessa.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Centessa Pharmaceuticals PLC ADR (CNTA)

CNTA Stock Overview

Market Cap in USD 904m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2021-05-28

CNTA Stock Ratings

Fundamental -9.07
Dividend -
Growth 5y -2.19
Rel. Performance vs Sector 10.89
Analysts 4.50
Fair Price Total Ret. 15.35
Fair Price DCF -

CNTA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

CNTA Growth Ratios

Growth 12m 230.63%
Growth Correlation 12m 66%
Growth Correlation 3m 69%
CAGR 5y -21.97%
CAGR / Mean Drawdown -0.33
Sharpe Ratio 12m 2.80
Alpha vs SP500 12m 213.31
Beta vs SP500 5y weekly 0.49
CAPM 6.56%
Average Daily Range 2m 7.95%
Regime Oscillator 92.87
Volatility GJR Garch 1y 98.00%
Price / SMA 50 34.6%
Price / SMA 200 62.87%
Current Volume 327.8k
Average Volume 20d 788.1k

External Links for CNTA Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of CNTA stocks?
As of February 24, 2024, the stock is trading at USD 11.01 with a total of 327,836 shares traded.
Over the past week, the price has changed by -6.30%, over one month by +36.94%, over three months by +63.11% and over the past year by +226.71%.
Why is CNTA stock down?
Check with which Index or Commodity CNTA has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return CNTA Return S&P 500
1 Month 36.94% 4.74%
3 Months 63.11% 11.99%
12 Months 226.71% 28.68%
What is the forecast for CNTA stock price target?
According to ValueRays Forecast Model, CNTA Centessa Pharmaceuticals PLC ADR will be worth about 16.6 in February 2025. The stock is currently trading at 11.01. This means that the stock has a potential upside of +50.68%.
Issuer Forecast Upside
Wallstreet Target Price 13 18.1%
Analysts Target Price 8.8 -20.1%
ValueRay Target Price 16.6 50.7%